REGULATORY
Interest Shown in Development of 3 Unapproved Drugs/Indications Including Metyrosine
Three more of the 13 unapproved drugs/indications with unmet medical needs for which the Ministry of Health, Labor and Welfare (MHLW) invited development sponsors in April has found their development sponsors. The three drugs are 1) metyrosine for pheochromocytoma, 2)…
To read the full story
Related Article
- Ono Files Metyrosine in Japan
April 27, 2018
REGULATORY
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
- MHLW to Set Criteria for Exemptions under OTC-Like Drug Charge Scheme
April 16, 2026
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





